Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128878 | 0.86 | CYP2C9 (0.54) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL20128502 | 0.85 | ACACB (0.43) | ACACBPARP15PARP10PARP2 | |
| SCHEMBL20126267 | 0.84 | S1PR3 (0.37) | ACACBCYP2C9 | |
| SCHEMBL20128691 | 0.82 | KDM1A (0.36) | ACACBCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL9618337 | 0.81 | CYP2C9 (0.54) | ACACBCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL9618338 | 0.81 | CYP2C9 (0.54) | ACACBCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL20129351 | 0.79 | MAPT (0.40) | ACACBCYP2C9ALDH1A1MAPTMEN1 | |
| SCHEMBL20126244 | 0.78 | DRD2 (0.39) | ACACB | |
| SCHEMBL9775621 | 0.78 | CYP2C9 (0.50) | ACACBCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL20129423 | 0.77 | CYP2C9 (0.44) | CYP2C9ALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | ACACB 3969/4885CYP2C9 348/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.